Abuse-Deterrent Opioid Formulations: A Key Ingredient in the Recipe to Prevent Opioid Disasters?

  • Aaron J. Salwan
  • Nicholas E. Hagemeier
  • Sam Harirforoosh
Current Opinion
  • 6 Downloads

Abstract

The US Food and Drug Administration (FDA) is encouraging the innovation of long-acting opioid formulations that are manipulation-resistant. The purpose of this commentary is to assess the benefits and limitations of abuse-deterrent opioid formulations (ADFs) and discuss their role in mitigating the current opioid epidemic. ADFs have been created with chemical properties that make it difficult for people who non-medically use prescription drugs to crush and dissolve opioid tablets, as well as by combining opioids with antagonists such as naloxone or naltrexone, which are released only when the dosage form has been manipulated or the drug is taken by a non-intended route. Despite these and other technologies, consensus regarding the effectiveness of these formulations in preventing non-medical use is lacking given the difficulty in obtaining post-marketing data. Researchers also question if the creation of abuse-deterrent drugs will have a positive effect on those struggling with a severe opioid-use disorder, fearing that current opioid users will simply find a new – perhaps more dangerous – drug of choice. Abuse-deterrent opioids are still opioids, and although they may make manipulation more difficult than non-ADF formulations, they are not “abuse proof.” The introduction of ADFs could provide a false sense of security among prescribers and dispensers, and we fear that ADFs may have a minimal impact on non-medical use of prescription opioids. Further epidemiological studies will be required to determine the large-scale impact of abuse-deterrent opioids in preventing opioid use disorder and its downstream consequences.

Notes

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest.

Funding

The authors declare that no sources of funding were used to prepare this article.

References

  1. 1.
    Throckmorton DC. Presentation: FDA Perspective on Abuse-Deterrent Opioid Development. 2017. https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM545923.pdf. Accessed 20 Dec 2017.
  2. 2.
    Farre M, Cami J. Pharmacokinetic considerations in abuse liability evaluation. Br J Addict. 1991;86(12):1601–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Hasin DS, O’Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry. 2013;170(8):834–51.  https://doi.org/10.1176/appi.ajp.2013.12060782.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Smith SM, Dart RC, Katz NP, Paillard F, Adams EH, Comer SD, et al. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154(11):2287–96.  https://doi.org/10.1016/j.pain.2013.05.053.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    U.S. Food and Drug Administration. Abuse-Deterrent Opioids. 2017. https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm337066.htm. Accessed Dec 18 2017.
  6. 6.
    U.S. Food and Drug Administration. Guidance for Industry. 2015. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf. Accessed Dec 13 2017.
  7. 7.
    Becker WC, Fiellin DA. Abuse-deterrent opioid formulations—putting the potential benefits into perspective. N Engl J Med. 2017;376(22):2103–5.  https://doi.org/10.1056/NEJMp1701553.CrossRefPubMedGoogle Scholar
  8. 8.
    Stanos SP, Bruckenthal P, Barkin RL. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering. Mayo Clinic Proc. 2012;87(7):683–94.  https://doi.org/10.1016/j.mayocp.2012.02.022.CrossRefGoogle Scholar
  9. 9.
    Budman SH, Grimes Serrano JM, Butler SF. Can abuse deterrent formulations make a difference? Expectation and speculation. Harm Reduct J. 2009;6:8.  https://doi.org/10.1186/1477-7517-6-8.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Schneider JP, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse? CNS Drugs. 2010;24(10):805–10.  https://doi.org/10.2165/11584260-000000000-00000.CrossRefPubMedGoogle Scholar
  11. 11.
    Katz N, Sun S, Johnson F, Stauffer J. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. J Pain. 2010;11(4):303–11.  https://doi.org/10.1016/j.jpain.2009.07.017.CrossRefPubMedGoogle Scholar
  12. 12.
    Walter C, Knothe C, Lotsch J. Abuse-deterrent opioid formulations: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2016;55(7):751–67.  https://doi.org/10.1007/s40262-015-0362-3.CrossRefPubMedGoogle Scholar
  13. 13.
    Webster LR, Bath B, Medve RA. Opioid formulations in development designed to curtail abuse: who is the target? Expert Opin Investig Drugs. 2009;18(3):255–63.  https://doi.org/10.1517/13543780902751622.CrossRefPubMedGoogle Scholar
  14. 14.
    Raffa RB, Pergolizzi JV Jr. Opioid formulations designed to resist/deter abuse. Drugs. 2010;70(13):1657–75.  https://doi.org/10.2165/11537940-000000000-00000.CrossRefPubMedGoogle Scholar
  15. 15.
    Bannwarth B. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose? Drugs. 2012;72(13):1713–23.  https://doi.org/10.2165/11635860-000000000-00000.CrossRefPubMedGoogle Scholar
  16. 16.
    Gudin JA, Nalamachu SR. An overview of prodrug technology and its application for developing abuse-deterrent opioids. Postgrad Med. 2016;128(1):97–105.  https://doi.org/10.1080/00325481.2016.1126186.CrossRefPubMedGoogle Scholar
  17. 17.
    Webster L, St Marie B, McCarberg B, Passik SD, Panchal SJ, Voth E. Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain. J Opioid Manag. 2011;7(3):235–45.CrossRefPubMedGoogle Scholar
  18. 18.
    Hays LR. A profile of OxyContin addiction. J Addict Dis. 2004;23(4):1–9.  https://doi.org/10.1300/J069v23n04_01.CrossRefPubMedGoogle Scholar
  19. 19.
    Butler SF, Black RA, Serrano JM, Wood ME, Budman SH. Characteristics of prescription opioid abusers in treatment: prescription opioid use history, age, use patterns, and functional severity. J Opioid Manag. 2010;6(4):239–41, 246–52.CrossRefPubMedGoogle Scholar
  20. 20.
    Passik SD, Hays L, Eisner N, Kirsh KL. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother. 2006;20(2):5–13.CrossRefPubMedGoogle Scholar
  21. 21.
    Katz NP, Buse DC, Budman SH, Wing Venuti S, Fernandez KC, Benoit C, et al. Development and preliminary experience with an ease of extractability rating system for prescription opioids. Drug Dev Indus Pharm. 2006;32(6):727–46.  https://doi.org/10.1080/03639040500529093.CrossRefGoogle Scholar
  22. 22.
    Gasior M, Bond M, Malamut R. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations. Postgrad Med. 2016;128(1):85–96.  https://doi.org/10.1080/00325481.2016.1120642.CrossRefPubMedGoogle Scholar
  23. 23.
    Centers for Disease Control and Prevention. HIV and Injection Drug Use. 2016. https://www.cdc.gov/vitalsigns/hiv-drug-use/index.html. Accessed 20 Dec 2017.
  24. 24.
    Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007;18(5):352–8.  https://doi.org/10.1016/j.drugpo.2007.04.004.CrossRefPubMedGoogle Scholar
  25. 25.
    Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep. 2008;10(1):11–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Cicero TJ, Ellis MS. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from oxyContin. JAMA Psychiatry. 2015;72(5):424–30.  https://doi.org/10.1001/jamapsychiatry.2014.3043.CrossRefPubMedGoogle Scholar
  27. 27.
    Topp L, Day C, Degenhardt L. Changes in patterns of drug injection concurrent with a sustained reduction in the availability of heroin in Australia. Drug Alcohol Depend. 2003;70(3):275–86.CrossRefPubMedGoogle Scholar
  28. 28.
    Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559–74.  https://doi.org/10.1146/annurev-publhealth-031914-122957.CrossRefPubMedGoogle Scholar
  29. 29.
    Twillman R, Fudin J. Potential cost-shifting and hidden costs and risks in the economic analysis of opioid abuse-deterrent formulations. Pain Med (Malden, Mass). 2014;15(9):1447–9.  https://doi.org/10.1111/pme.12500.
  30. 30.
    Keast SL, Owora A, Nesser N, Farmer K. Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program. J Managed Care Spec Pharm. 2016;22(4):347–56.  https://doi.org/10.18553/jmcp.2016.22.4.347.CrossRefGoogle Scholar
  31. 31.
    Good CB. Presentation: Abuse-Deterrent Opioid Formulations. 2016. https://www.fda.gov/downloads/Drugs/NewsEvents/UCM527924.pdf. Accessed 20 Dec 2017.
  32. 32.
    Joranson DE, Gilson AM. Drug crime is a source of abused pain medications in the United States. J Pain Symptom Manage. vol 4. United States 2005. p. 299–301.Google Scholar
  33. 33.
    Substance Abuse and Mental Health Services Administration. Results from the 2015 National Survey on Drug Use and Health: Detailed Tables. 2016. https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015.htm. Accessed 20 Dec 2017.
  34. 34.
    Hagemeier NE, Tudiver F, Brewster S, Hagy EJ, Hagaman A, Pack RP. Prescription drug abuse communication: A qualitative analysis of prescriber and pharmacist perceptions and behaviors. Res Social Adm Pharm. 2016;12(6):937–48.  https://doi.org/10.1016/j.sapharm.2015.12.008.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pharmacy Practice, Gatton College of PharmacyEast Tennessee State UniversityJohnson CityUSA
  2. 2.Department of Pharmaceutical Sciences, Gatton College of PharmacyEast Tennessee State UniversityJohnson CityUSA

Personalised recommendations